WPI 2287 (Propafenone Hydrochloride Extended-Release 425 mg)
Pill with imprint WPI 2287 is White, Capsule-shape and has been identified as Propafenone Hydrochloride Extended-Release 425 mg. It is supplied by Actavis Pharma, Inc..
Propafenone is used in the treatment of atrial fibrillation; atrial flutter; ventricular tachycardia; wolff-parkinson-white syndrome and belongs to the drug class group I antiarrhythmics. Risk cannot be ruled out during pregnancy. Propafenone 425 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for WPI 2287
More about propafenone
- Propafenone Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 49 Reviews
- Drug class: group I antiarrhythmics
- Propafenone Tablets
- Propafenone Sustained-Release Capsules
- Propafenone (Advanced Reading)
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.